Redeye: Xspray Pharma - Catalysts coming

Although the corona crisis has delayed Xspray’s clinical trials, a review of this significantly de-risked case leads us to raise estimates and fair value. With key catalysts due this year, we highlight the overlooked stock’s undemanding valuation – which puts HyNap-Dasa’s chance of reaching the market at just 30%, versus our 80% – and clear upside potential.

Read more and download the research update: https://bit.ly/2KfT67m

Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/